GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq: GNVC) announced today that the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), has executed its first option period (year two) under a previously announced five-year, $52 million contract with GenVec for the production of HIV vaccines. GenVec will receive up to $5.1 million for the second year of activities. These funds will support the transfer and scale-up of the company’s manufacturing and purification technologies to the NIAID Dale and Betty Bumpers Vaccine Research Center’s (VRC) Vaccine Pilot Plant in Frederick, Maryland, which produces materials for clinical research.
